Browse our anti-CDKN1A (CDKN1A) Antibodies

Full name:
anti-Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) Antibodies (CDKN1A)
On www.antibodies-online.com are 581 Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A) Antibodies from 25 different suppliers available. Additionally we are shipping CDKN1A Kits (24) and CDKN1A Proteins (16) and many more products for this protein. A total of 658 CDKN1A products are currently listed.
Synonyms:
CAP20, CCND1, CDKI, Cdkn1, CDKN1A, CIP1, MDA-6, mda6, p16Xic2, P21, p21Cip1, p21WAF, SDI1, si:ch1073-48m5.2, UV96, WAF1
list all antibodies Gene Name GeneID UniProt
CDKN1A 114851  
CDKN1A 1026 P38936
CDKN1A 12575 P39689

Show all species

Show all synonyms

All available anti-CDKN1A Antibodies

Go to our pre-filtered search.

Top referenced anti-CDKN1A Antibodies

  1. Human Polyclonal CDKN1A Primary Antibody for FACS, IF - ABIN391763 : Fukuchi, Nakamura, Ichimura, Tatsumi, Gomi: The association of cyclin A and cyclin kinase inhibitor p21 in response to gamma-irradiation requires the CDK2 binding region, but not the Cy motif. in Biochimica et biophysica acta 2003 (PubMed)
    Show all 5 references for 391763

  2. Human Polyclonal CDKN1A Primary Antibody for DB, EIA - ABIN358179 : Scott, Kimura, Dong, Ichinohasama, Bergen, Kerviche, Sheridan, DeCoteau: Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia. in Leukemia research 2004 (PubMed)
    Show all 5 references for 358179

  3. Human Polyclonal CDKN1A Primary Antibody for EIA, IHC (p) - ABIN358182 : Amini, Saunders, Kelley, Khalili, Sawaya: Interplay between HIV-1 Vpr and Sp1 modulates p21(WAF1) gene expression in human astrocytes. in The Journal of biological chemistry 2004 (PubMed)
    Show all 5 references for 358182

  4. Human Polyclonal CDKN1A Primary Antibody for EIA, IHC (p) - ABIN359673 : Frouin, Maga, Denegri, Riva, Savio, Spadari, Prosperi, Scovassi: Human proliferating cell nuclear antigen, poly(ADP-ribose) polymerase-1, and p21waf1/cip1. A dynamic exchange of partners. in The Journal of biological chemistry 2003 (PubMed)
    Show all 5 references for 359673

  5. Human Polyclonal CDKN1A Primary Antibody for IF, WB - ABIN653259 : Chen, Turner, McCarthy, Scaltriti, Bettuzzi, Yeatman: Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. in Cancer research 2004 (PubMed)
    Show all 3 references for 653259

  6. Human Polyclonal CDKN1A Primary Antibody for WB - ABIN655723 : Noma, Kirino, Ikeuchi, Suzuki: Biosynthesis of wybutosine, a hyper-modified nucleoside in eukaryotic phenylalanine tRNA. in The EMBO journal 2006 (PubMed)
    Show all 2 references for 655723

  7. Human Monoclonal CDKN1A Primary Antibody for FACS, IHC (p) - ABIN180466 : Buckley, Sweeney, Hamilton, Sini, Manning, Nicholson, deFazio, Watts, Musgrove, Sutherland: Expression and amplification of cyclin genes in human breast cancer. in Oncogene 1993 (PubMed)
    Show all 2 references for 180466

  8. Human Polyclonal CDKN1A Primary Antibody for IF, IHC (p) - ABIN657391 : Hu, Gartenhaus, Eichberg, Liu, Fang, Rapoport: PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21. in Oncogene 2010 (PubMed)

  9. Human Polyclonal CDKN1A Primary Antibody for EIA, IHC (p) - ABIN358181 : Marqués, Kumar, Poveda, Zuluaga, Hernández, Jackson, Pasero, Carrera: Specific function of phosphoinositide 3-kinase beta in the control of DNA replication. in Proceedings of the National Academy of Sciences of the United States of America 2009 (PubMed)

More Antibodies against CDKN1A Interaction Partners

Zebrafish Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A) interaction partners

  1. We characterized the effect of the novel loci through pathway analysis and found that pathways involved are not entirely distinct as assumed so far. Further, we identified a novel association between CDKN1A and POAG. Using a zebrafish model we show that six6b (associated with POAG and optic nerve head variation) alters the expression of cdkn1a

  2. intestinal clock controls the expression of key cell cycle regulators, such as cdc2 (show CDK1 Antibodies), wee1 (show WEE1 Antibodies), p21, PCNA (show PCNA Antibodies) and cdk2 (show CDK2 Antibodies), but only weakly influences cyclin B1 (show CCNB1 Antibodies), cyclin B2 (show CCNB2 Antibodies) and cyclin E1 (show CCNE1 Antibodies) expression.

Human Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A) interaction partners

  1. SUMO and p21Cip1 regulate the transit of proteins through the nucleolus; disruption of nucleolar export by DNA damage induces SUMO and p21Cip1 to act as hub proteins to form a multiprotein complex in the nucleolus.

  2. HULC activates p53 (show TP53 Antibodies)-p21 pathway and promotes nasopharyngeal carcinoma cell growth.

  3. We characterized the effect of the novel loci through pathway analysis and found that pathways involved are not entirely distinct as assumed so far. Further, we identified a novel association between CDKN1A and POAG. Using a zebrafish model we show that six6b (associated with POAG and optic nerve head variation) alters the expression of cdkn1a

  4. miRNAs miR (show MLXIP Antibodies)-106b and miR (show MLXIP Antibodies)-20a that target p21 were specifically downregulated in HIV-1 infected CD4 (show CD4 Antibodies)+ T cells.

  5. Increased nuclear localization of p21(WAF1/CIP1) in SPRY2 (show SPRY2 Antibodies) downregulated colon cancer cells may explain the inhibition of cell proliferation in colon cancer cells.

  6. This article discusses the controversial aspects of the two-faced involvement of p21 in cancer and speculate on how this new information may increase our understanding of its role in cancer pathogenesis. Prevailing notions indicate that p21 might also act as antiapoptotic agent, which may have relevant implications for future therapeutic strategies. [review]

  7. In this study, we found upregulation of several hemostasis-related genes, including the thrombin (show F2 Antibodies)-activatable receptor PAR-1 (protease-activated receptor-1 (show F2R Antibodies)), in Runx1 (show RUNX1 Antibodies)/Cbfb (show CBFB Antibodies)-deleted MLL (show MLL Antibodies)-AF9 (show MLLT3 Antibodies) cells. Similar to the effect of Runx1 (show RUNX1 Antibodies)/Cbfb (show CBFB Antibodies) deletion, PAR-1 (show MARK2 Antibodies) overexpression induced CDKN1A/p21 expression and attenuated proliferation in MLL (show MLL Antibodies)-AF9 (show MLLT3 Antibodies) cells

  8. Results provide evidence that Foxp3 (show FOXP3 Antibodies) is a downstream target of p53 (show TP53 Antibodies) and that is sufficient to induce p21 expression, ROS (show ROS1 Antibodies) production and p53 (show TP53 Antibodies)-mediated senescence.

  9. both in vitro and in vivo studies proved that CypD (show CYPD Antibodies) inhibitor-based treatment was able to efficiently impair this interaction, leading to a tumor formation reduction. All together, these findings indicate that the countering effect of CypD (show CYPD Antibodies) on the p53 (show TP53 Antibodies)-p21 pathway participates in oncogene (show RAB1A Antibodies)-dependent transformation.

  10. The deletion of CBX3 (show CBX3 Antibodies) directly enforces the expression of CDK6 (show CDK6 Antibodies) and p21.

Cow (Bovine) Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A) interaction partners

  1. p21 expression reports on Bovine herpesvirus 4 replication and could represent a host cell defensive response to infection-associated cellular damage.

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A) interaction partners

  1. Data show that Emu-Myc (show MYC Antibodies) mice lacking both p21 (show D4S234E Antibodies) and PUMA (show BBC3 Antibodies) developed lymphoma at a rate considerably longer latency than Emu-Myc (show MYC Antibodies);p53 (show TP53 Antibodies)(+/-)mice.

  2. Study reports that p27 (show CDKN1B Antibodies) normally exerts a negative feedback on p21 (show D4S234E Antibodies) expression: p27 (show CDKN1B Antibodies) directly represses the expression of the transcription factor Pitx2 (show PITX2 Antibodies) which in turn maintains decreased p21 (show D4S234E Antibodies) levels. Consequently, in cells lacking p27 (show CDKN1B Antibodies), de-repression of Pitx2 (show PITX2 Antibodies) causes the up-regulation of p21 (show D4S234E Antibodies) showing a new mechanism by which p27 (show CDKN1B Antibodies) regulates cell cycle progression by transcriptionally regulating the expression of Pitx2 (show PITX2 Antibodies) and p21 (show D4S234E Antibodies).

  3. p21 (show D4S234E Antibodies)-associated inhibition of early-stage malignant progression and the intense expression in papilloma outgrowths, identifies a novel, significant antagonism between p21 (show D4S234E Antibodies) and ras(Ha)/ROCK2 (show ROCK2 Antibodies)/NF-kappaB (show NFKB1 Antibodies) signalling in skin carcinogenesis.these data show that ROCK2 (show ROCK2 Antibodies) activation induces malignancy in ras(Ha)-initiated/promoted papillomas in the context of p53 (show TP53 Antibodies) loss and novel NF-kappaB (show NFKB1 Antibodies) expression

  4. In this study, we found upregulation of several hemostasis-related genes, including the thrombin (show F2 Antibodies)-activatable receptor PAR-1 (protease-activated receptor-1 (show F2R Antibodies)), in Runx1 (show RUNX1 Antibodies)/Cbfb (show CBFB Antibodies)-deleted MLL (show MLL Antibodies)-AF9 (show MLLT3 Antibodies) cells. Similar to the effect of Runx1 (show RUNX1 Antibodies)/Cbfb (show CBFB Antibodies) deletion, PAR-1 (show MARK2 Antibodies) overexpression induced CDKN1A/p21 expression and attenuated proliferation in MLL (show MLL Antibodies)-AF9 (show MLLT3 Antibodies) cells

  5. both in vitro and in vivo studies proved that CypD (show CYPD Antibodies) inhibitor-based treatment was able to efficiently impair this interaction, leading to a tumor formation reduction. All together, these findings indicate that the countering effect of CypD (show CYPD Antibodies) on the p53 (show TP53 Antibodies)-p21 (show D4S234E Antibodies) pathway participates in oncogene (show RAB1A Antibodies)-dependent transformation.

  6. FLT3 (show FLT3 Antibodies)-ITD is capable of inhibiting FLT3 (show FLT3 Antibodies)-ITD+ cell proliferation through the p21 (show D4S234E Antibodies)/Pbx1 (show PBX1 Antibodies) axis

  7. These data reveal a novel role for p21/waf1 in the resolution of inflammation via its ability to control neutrophil apoptosis.

  8. the silencing of Cyclin-dependent kinase 5 (show CDK5 Antibodies) preventing memory dysfunction

  9. Results show that p21 (show D4S234E Antibodies) expression is regulated by OLA1 (show OLA1 Antibodies) to promote cell proliferation and organogenesis.

  10. AS160 (show TBC1D4 Antibodies) regulates glucose-independent eukaryotic cell proliferation through p21 (show D4S234E Antibodies)-dependent control of the cell cycle.

CDKN1A Antigen Profile

Antigen Summary

This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene.

Alternative names and synonyms associated with CDKN1A

  • cyclin-dependent kinase inhibitor 1A (p21, Cip1) (cdkn1a) antibody
  • cyclin-dependent kinase inhibitor 1 (cki1) antibody
  • cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) antibody
  • cyclin-dependent kinase inhibitor 1A (cdkn1a) antibody
  • cyclin-dependent kinase inhibitor 1A (LOC100348489) antibody
  • cyclin-dependent kinase inhibitor 1A (Cdkn1a) antibody
  • cyclin-dependent kinase inhibitor 1A (p21, Cip1) (Cdkn1a) antibody
  • cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a) antibody
  • CAP20 antibody
  • CCND1 antibody
  • CDKI antibody
  • Cdkn1 antibody
  • CDKN1A antibody
  • CIP1 antibody
  • MDA-6 antibody
  • mda6 antibody
  • p16Xic2 antibody
  • P21 antibody
  • p21Cip1 antibody
  • p21WAF antibody
  • SDI1 antibody
  • si:ch1073-48m5.2 antibody
  • UV96 antibody
  • WAF1 antibody

Protein level used designations for CDKN1A

cyclin dependent kinase inhibitor p16Xic2 , cyclin-dependent kinase inhibitor 1 , cyclin D1 , cyclin-dependent kinase inhibitor 1A (p21, Cip1) , cip1 , p21 , waf1 , cyclin-dependent kinase inhibitor 1A , cyclin-dependent kinase inhibitor 1A (P21) , CDK-interacting protein 1 , CDK-interaction protein 1 , DNA synthesis inhibitor , melanoma differentiation associated protein 6 , wild-type p53-activated fragment 1 , p21/WAF1 , melanoma differentiation-associated protein , p21

GENE ID SPECIES
492305 Xenopus laevis
606440 Zea mays
747442 Pan troglodytes
100038054 Xenopus (Silurana) tropicalis
100302083 Ovis aries
100151416 Danio rerio
100348489 Oryctolagus cuniculus
114851 Rattus norvegicus
1026 Homo sapiens
474890 Canis lupus familiaris
513497 Bos taurus
100152215 Sus scrofa
100720449 Cavia porcellus
493943 Felis catus
12575 Mus musculus
Selected quality suppliers for anti-CDKN1A (CDKN1A) Antibodies
Did you look for something else?